Table 2.

Approved indications for HCT in India for children and adolescents (adopted from EBMT).⁵

Disease	Disease status	MSD Allo	MUD Allo	MMAD Allo	Auto
Hematological malignancies
AML	CR1 (low risk) CR1 (high and very high risk) CR2 >CR2	GNR/II S/II S/II S/II	GNR/II S/II S/II CO/II	GNR/III CO/II S/II CO/II	GNR/II GNR/II GNR/II GNR/II
ALL	CR1 (low risk) CR1 (high risk) CR2 >CR2	GNR/II S/II S/II S/II	GNR/II S/II S/II S/II	GNR/III CO/II CO/II CO/II	GNR/II GNR/II GNR/II GNR/II
CML	First CP, failing second- or third-line TKI Accelerated phase, blast crisis or > first CP	S/II S/II	S/II S/II	CO/II CO/II	GNR/III GNR/III
MDS and JMML		S/II	S/II	CO/III	GNR/III
NHL	CR1 (low risk) CR1 (high risk) CR2	GNR/II CO/II S/II	GNR/II CO/II S/II	GNR/II CO/II CO/II	GNR/II CO/II CO/II
HL	CR1 First relapse, CR2	GNR/II CO/II	GNR/II CO/III	GNR/II CO/III	GNR/II S/II
Non-malignant disorders and solid tumours
Primary ID	Severe combined ID Other primary ID	S/II S/II	S/II S/II	S/II CO/II	NA NA
MPS	MPS-1H Hurler MPS-1H Hurler Scheie (severe) MPS-VI Maroteaux-Lamy	S/II GNR/III CO/II	S/II GNR/III CO/II	CO/II GNR/III CO/II	NA NA NA
Thalassemia and SCD		S/II	CO/II	CO/II	NA
Osteopetrosis		S/II	S/II	S/II	NA
Acquired SAA		S/II	S/II	CO/II	NA
IBMFS		S/II	S/II	CO/II	NA
Germ cell tumours		CO/II	CO/II	CO/II	CO/II
Sarcoma	Ewing's sarcoma (high risk or > CR1)	D/II	D/III	D/III	S/II
	Soft tissue sarcoma (high risk or > CR1)	D/II	D/II	D/III	CO/II
	Osteogenic sarcoma	GNR/III	GNR/III	GNR/III	D/II
	Ewing's sarcoma (high risk or > CR1)	D/II	D/III	D/III	S/II
Neuroblastoma	High risk or > CR1	CO/II	CO/II	D/III	S/II
Brain tumours		GNR/III	GNR/III	GNR/III	CO/II
Wilms' tumour	>CR1	GNR/III	GNR/III	GNR/III	CO/II
AD	Including monogenic AD	CO/II	CO/II	CO/II	CO/II

Abbreviations: AD autoimmune disorders, ALL acute lymphoblastic leukaemia, Allo allogeneic transplantation, AML acute myeloid leukaemia, Auto autologous transplantation, CML chronic myelogenous leukaemia, CO clinical option (can be carried after careful assessment of risks and benefits), CR1, 2 first, second complete remission, D developmental (further trials are needed), GNR generally not recommended, HL Hodgkin lymphoma, HCT haematopoietic stem cell transplantation, IBMFS inborn marrow failure syndromes (Fanconi anemia, dyskeratosis congenita, Blackfan–Diamond anemia and others), ID immunodeficiency, JMML juvenile myelomonocytic leukaemia, MDS myelodysplastic syndromes, MMAD mismatched alternative donors (cord blood, haploidentical and mismatched unrelated donors), MPS mucopolysaccharidosis, MSD matched sibling donor, MUD well-matched unrelated donor (8/8, 10/10 or 9/10 if mismatched is in DQB1), S standard of care (generally indicated in suitable patients), SAA severe aplastic anemia, SCD sickle cell disease (high risk).